Arisaph Pharmaceuticals, Inc. is an emerging drug discovery and design biopharmaceutical company located in Boston, Massachusetts, an internationally recognized center of biotechnology. The company utilizes proprietary drug discovery platforms to develop differentiated drugs that are highly potent and act on select targets for the treatment of a variety of diseases.  Such drugs are expected to produce improvements in safety, efficacy and tolerability.  Arisaph currently has seven drug discovery programs to develop therapies for cancer, cardiovascular disorders and diabetes.

Arisaph has successfully applied its proprietary specificity profiling and retro-inverso chiral chemistry technology platforms to synthesize several promising lead drug candidates, including a DPP IV inhibitor for type II diabetes and reverse D-4F, an orally active apo A-I mimetic peptide for the treatment of atherosclerosis. Additionally, the Company has designed and synthesized promising leads for two targets of HDL ("good") cholesterol modulation and for a validated cancer target.  Through a license agreement with Tufts University, Arisaph has exclusive worldwide rights to several important issued patents in the diabetes area and to several pending patent applications covering the Company’s drug discovery platforms for use in developing therapies to treat several diseases.